Cargando…
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis
Activation of Sirtuin (silent mating type information regulation 2 homolog) 1, or SIRT1, is an unexplored therapeutic approach for treatment of inflammatory diseases. We randomized 40 patients with moderate-to-severe psoriasis (4:1) to three escalating doses of SRT2104, a selective activator of SIRT...
Autores principales: | Krueger, James G., Suárez-Fariñas, Mayte, Cueto, Inna, Khacherian, Artemis, Matheson, Robert, Parish, Lawrence C., Leonardi, Craig, Shortino, Denise, Gupta, Akanksha, Haddad, Jonathan, Vlasuk, George P., Jacobson, Eric W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640558/ https://www.ncbi.nlm.nih.gov/pubmed/26556603 http://dx.doi.org/10.1371/journal.pone.0142081 |
Ejemplares similares
-
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers
por: Libri, Vincenzo, et al.
Publicado: (2012) -
Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in Otherwise Healthy Cigarette Smokers
por: Venkatasubramanian, Sowmya, et al.
Publicado: (2013) -
Sirtuin 1 activator SRT2104 protects Huntington's disease mice
por: Jiang, Mali, et al.
Publicado: (2014) -
Neuroprotection of SRT2104 in Murine Ischemia/Reperfusion Injury Through the Enhancement of Sirt1-Mediated Deacetylation
por: Bai, Xue, et al.
Publicado: (2023) -
Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis
por: Sands, Bruce E., et al.
Publicado: (2015)